Atlantic Equities analyst Steve Chesney maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $220 to $295.
Regeneron Pharma’s Pipeline Makes This Analyst Turn Bullish
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)